Browsing Tag
cholestatic liver disease
2 posts
How the cholestatic liver disease market is creating new opportunities for NTCP-targeting therapies
Assembly Biosciences is expanding ABI-6250 into PBC and PSC. Find out why NTCP-targeting therapies are gaining momentum in hepatology.
GENFIT begins phase 3 trial of elafibranor in primary biliary cholangitis
GENFIT has started the phase 3 ELATIVE clinical trial for evaluating the efficacy and safety of elafibranor for…